[The fibroblast growth factor as a predictor of symptomatic change under combined pharmacological treatment of benign prostatic hyperplasia].
The results of our study showed, that long-term combined medical treatment of benign prostatic hyperplasia (Finasteride 5 mg/day + Tamsulosin 0.4 mg/day) significantly decreases values of IPSS and residual urine volume (RUV) in patients, which basic level of bFGF in serum does not exceed 5.9 pg/ml. On the other hand pharmacological treatment was insufficient in patients with bFGF basic level equal or more than 5.9 pg/ml; values of IPSS and RUV did not decrease.